SAFETY AND EFFICACY OF REGORAFENIB IN JAPANESE PATIENTS WITH METASTATIC COLORECTAL CANCER: A SUBGROUP ANALYSIS OF THE PHASE III CORRECT TRIAL

被引：0
|
作者：
Yamada, Y.
Yoshino, T. [1 ]
Komatsu, Y. [2 ]
Yamazaki, K. [3 ]
Tsuji, A. [4 ]
Ura, T. [5 ]
Grothey, A. [6 ]
Van Cutsem, E. [7 ]
Wagner, A. [8 ]
Ohtsu, A. [1 ]
机构：
[1] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[2] Hokkaido Univ Hosp, Sapporo, Hokkaido, Japan
[3] Shizuoka Canc Ctr, Shizuoka, Japan
[4] Kochi Hlth Sci Ctr, Kochi, Japan
[5] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[6] Mayo Clin Rochester, Rochester, MN USA
[7] Univ Hosp Gasthuisberg, Gasthuisberg, Belgium
[8] Bayer Pharma AG, Berlin, Germany
来源：
ANNALS OF ONCOLOGY | 2013年 / 24卷
关键词：
D O I：
10.1093/annonc/mdt459.81
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Time to health status deterioration in regorafenib-treated patients with metastatic colorectal cancer (mCRC): a post-hoc analysis of the phase III CORRECT study
    Stein, A.
    Pawar, V.
    Grothey, A.
    Sobrero, A.
    Siena, S.
    Falcone, A.
    Ychou, M.
    Lenz, H. J.
    Yoshino, T.
    Wagner, A.
    van Cutsem, E.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 40 - 40
  • [42] A prospective, observational trial to assess the safety and efficacy of regorafenib in patients with metastatic colorectal cancer (mCRC) in routine clinical practice (CORRELATE)
    Michel, Ducreux
    Alfredo, Falcone
    Punt, Cornelis J. A.
    Svetlana, Kobina
    Juan Manuel, O'Connor
    Andres, Cervantes
    ANNALS OF ONCOLOGY, 2016, 27 : 80 - 80
  • [43] Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study)
    Ricotta, Riccardo
    Verrioli, Antonella
    Ghezzi, Silvia
    Porcu, Luca
    Grothey, A.
    Falcone, Alfredo
    Van Cutsem, Eric
    Argiles, Guillem
    Adenis, Antoine
    Ychou, Marc
    Barone, Carlo
    Bouche, Olivier
    Peeters, Marc
    Humblet, Yves
    Mineur, Laurent
    Sobrero, Alberto F.
    Hubbard, Joleen M.
    Cremolini, Chiara
    Prenen, Hans
    Tabernero, Josep
    Jarraya, Hajer
    Mazard, Thibault
    Deguelte-Lardiere, Sophie
    Papadimitriou, Konstantinos
    Van den Eynde, Marc
    Pastorino, Alessandro
    Redaelli, Daniela
    Bencardino, Katia
    Funaioli, Chiara
    Amatu, Alessio
    Carlo-Stella, Giulia
    Torri, Valter
    Sartore-Bianchi, Andrea
    Vanzulli, Angelo
    Siena, Salvatore
    ESMO OPEN, 2016, 1 (06)
  • [44] Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: a retrospective cohort study
    Yan, Hao
    Liu, Jindong
    Zhang, Yifan
    Chen, Shuo
    Xu, Jing
    Gao, Dandan
    Li, Haipeng
    Fang, Xinyue
    Wang, Yu
    Wang, Huaqing
    Wang, Hui
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (03) : 987 - 1001
  • [45] A prospective, observational trial to assess the safety and efficacy of regorafenib in patients with metastatic colorectal cancer (mCRC) in routine clinical practice (CORRELATE)
    Ducreux, M.
    Falcone, A.
    Punt, C. J. A.
    Majdi, A.
    O'Connor, J. M.
    Cervantes, A.
    ANNALS OF ONCOLOGY, 2015, 26
  • [46] The efficacy and safety of sintilimab plus regorafenib in refractory metastatic colorectal cancer.
    Li, Rongrong
    Liu, Zhenyang
    Yin, Xianli
    Zeng, Deyu
    Jiang, Shaofeng
    Liu, Wu
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E15546 - E15546
  • [47] Characteristics and outcomes of patients enrolled in the CORRECT and CONCUR phase 3 trials of regorafenib for metastatic colorectal cancer (mCRC)
    Vogel, A.
    van Cutsem, E.
    Wagner, A.
    Kalmus, J.
    Qin, S.
    Kim, T. W.
    Li, J.
    Xu, R.
    Grothey, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 71 - 71
  • [48] Safety and efficacy of regorafenib in Japanese patients with metastatic colorectal cancer (mCRC) in clinical practice: Interim result from postmarketing surveillance (PMS).
    Komatsu, Yoshito
    Muro, Kei
    Yamaguchi, Kensei
    Uetake, Hiroyuki
    Satoh, Taroh
    Yoshino, Takayuki
    Nishida, Toshirou
    Yamazaki, Naoya
    Takigawa, Hajime
    Hamada, Yoko
    Chosa, Masayuki
    Sunaya, Toshiyuki
    Yamamoto, Yuka
    Ito, Yuichiro
    Watanabe, Toshiaki
    Sugihara, Kenichi
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [49] Exploratory analysis of baseline microsatellite instability (MSI) status in patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) or placebo in the phase 3 CORRECT trial
    Koechert, K.
    Beckmann, G.
    Teufel, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [50] Pharmacokinetics of regorafenib (REG) in the phase 3 CONCUR and CORRECT trials in patients (pts) with metastatic colorectal cancer (mCRC)
    Cleton, A.
    Sturm, I.
    Trnkova, Z. Jirakova
    Grevel, J.
    Fiala-Buskies, S.
    Lettieri, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 10 - 10
12345